AIM ImmunoTech Announces the Expansion of its Pancreatic Cancer Program to Include New Patients in the Netherlands

NEXT STORY
Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Accomplishments and Strategy for 2021
PREV STORY
Dry Mouth Relief Market Valuation to Surpass USD 2,777.14 Million by 2026, at 4.10% CAGR, Asserts Market Research Future (MRFR)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Checkpoint Therapeutics Initiates Phase 1 Study of Anti-PD-L1 Antibody CK-301

NEW YORK, Oct. 05, 2017 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a ...

author_avatar
NASDAQ Market News

PATIENT WITH “FLESH EATING DISEASE”ON HER LEG WALKS OUT OF SUNRISE HOSPITAL AND MEDICAL CENTER

Las Vegas, NV, June 01, 2017 (GLOBE NEWSWIRE) -- Sunrise Hospital and Medical Center ...

author_avatar
NASDAQ Market News

Tyme Inc. Appoints Dr. Jonathan Eckard as Chief Scientific Affairs Officer

NEW YORK, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies Inc. (Nasdaq:TYME), a clinical ...

author_avatar
NASDAQ Market News